STOCK TITAN

Nurix Therapeutics, Inc. - NRIX STOCK NEWS

Welcome to our dedicated page for Nurix Therapeutics news (Ticker: NRIX), a resource for investors and traders seeking the latest updates and insights on Nurix Therapeutics stock.

Nurix Therapeutics, Inc. (Nasdaq: NRIX) is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing innovative therapies that modulate cellular protein levels. Leveraging their proprietary drug discovery platform, DELigase, Nurix focuses on a novel approach to target E3 ubiquitin ligases within the ubiquitin-proteasome system (UPS). This system regulates protein stabilization and degradation, providing therapeutic opportunities across various disease areas.

Founded by experts in the UPS field and initially funded by leading investors such as Third Rock Ventures and The Column Group, Nurix has positioned itself as a leader in developing first-in-class therapies. The company’s pipeline includes drug candidates that target protein degraders of Bruton's tyrosine kinase (BTK) and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B). Their lead product candidate, NX-2127, is an orally available BTK degrader designed to treat relapsed or refractory B-cell malignancies. Another key candidate, NX-1607, is an orally available CBL-B inhibitor aimed at immuno-oncology indications.

Partnering with industry giants like Celgene, Sanofi, Gilead, and Pfizer, Nurix continues to expand its reach and capabilities. One significant collaboration with Sanofi targets the STAT6 pathway, a critical player in type 2 inflammation. The extension of this collaboration underscores the success and productivity of their ongoing research efforts. Nurix’s innovative approach is also evident in their BTK degrader NX-5948, demonstrating promising clinical activity in patients with CNS involvement.

In its recent financial update, Nurix reported strong results for the first quarter of 2024, with increased revenue driven by collaborations and research milestones. Despite reporting a net loss, the company holds substantial cash reserves to support ongoing and future projects. Leadership transitions within Nurix, such as the appointment of Julia P. Gregory as the new board chair, reflect the company’s commitment to strategic growth and innovation.

Headquartered in San Francisco, California, Nurix remains at the forefront of drug discovery and development, aiming to bring transformative therapies to patients with cancer, inflammatory conditions, and other challenging diseases. For more information, visit http://www.nurixtx.com.

Rhea-AI Summary

Nurix Therapeutics (Nasdaq: NRIX) has announced the pricing of its upsized public offering of 4,500,000 shares at $31.00 each, totaling gross proceeds of approximately $139.5 million. The offering, which includes a 30-day option for underwriters to purchase an additional 675,000 shares, is set to close on March 9, 2021. Notably, this offering aims to enhance the company’s financial flexibility to advance its pipeline of targeted protein modulation therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.43%
Tags
-
Rhea-AI Summary

Nurix Therapeutics, Inc. (NASDAQ: NRIX) announced a public offering of 4,000,000 shares of its common stock, with plans to grant underwriters a 30-day option for an additional 600,000 shares. The offering is managed by J.P. Morgan, Piper Sandler, and Stifel, subject to market conditions. A registration statement has been filed with the SEC but is not yet effective, and the offering is only made by means of a prospectus.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.08%
Tags
-
Rhea-AI Summary

Nurix Therapeutics (Nasdaq: NRIX) reported positive developments, including FDA clearance for its first IND application for NX-2127 targeting B-cell malignancies. The company also expanded its collaboration with Sanofi, resulting in a $22 million option exercise payment. Financially, Nurix ended 2020 with $372 million in cash and investments, up from $38.2 million in 2019. However, the company reported a net loss of $43.2 million for the fiscal year. Upcoming clinical trials for NX-2127 and NX-1607 are expected in 2021, indicating a promising year ahead.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.4%
Tags
Rhea-AI Summary

Nurix Therapeutics, Inc. (NRIX) announced an expansion of its collaboration with Sanofi, resulting in an additional payment of $22 million. This follows an upfront payment of $55 million received earlier. Sanofi will now explore five targets instead of three within this agreement. Nurix stands to gain up to $2.5 billion in total payments based on milestones in research and development. CEO Arthur T. Sands highlighted the productive nature of the collaboration, emphasizing progress in drug development for challenging diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.79%
Tags
none
-
Rhea-AI Summary

Nurix Therapeutics (NRIX) announced that CEO Arthur Sands will present a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021, at 3:40 p.m. EST. The presentation will be available via live webcast, with an archived version accessible for 30 days post-event. Nurix focuses on developing targeted protein modulation therapies for cancer and immune disorders, utilizing its proprietary DELigase platform to discover novel drug candidates.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.87%
Tags
none
-
Rhea-AI Summary

Nurix Therapeutics (NRIX) announced key preclinical data for NX-2127, targeting B-cell malignancies, at the 62nd American Society of Hematology Annual Meeting. The company plans to initiate a Phase 1 clinical trial for relapsed or refractory non-Hodgkin’s lymphoma and chronic lymphocytic leukemia in H1 2021. NX-2127 is designed to overcome resistance in B-cell cancers by degrading Bruton’s tyrosine kinase (BTK) and activating T-cells, showing promising anti-tumor effects in preclinical models.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.44%
Tags
Rhea-AI Summary

Nurix Therapeutics (Nasdaq: NRIX), a biopharmaceutical firm, has announced its participation in two upcoming virtual healthcare conferences. The Stifel 2020 Virtual Healthcare Conference will take place from November 16-18, 2020, with CEO Arthur Sands presenting on November 17 at 3:20 p.m. EST. The Piper Sandler 32nd Annual Virtual Healthcare Conference will follow from December 1-3, 2020, featuring Sands on December 1. Both presentations will be available for 30 days afterward on Nurix's Events and Presentations page.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.47%
Tags
conferences
-
Rhea-AI Summary

Nurix Therapeutics (NRIX) announced presentations at two significant upcoming events: the 5th Medicinal Chemistry & Protein Degradation Summit and the 62nd ASH Annual Meeting. Key highlights include data on their targeted protein degradation platform and preclinical data for NX-2127, aimed at treating B-cell malignancies. The summit presentation is by Senior Scientist Dan Robbins on November 16, focusing on new therapeutic discovery, while the ASH meeting will feature NX-2127's effects on B-cell malignancies on December 7.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.64%
Tags
conferences clinical trial
-
Rhea-AI Summary

Nurix Therapeutics (Nasdaq: NRIX) announced the resignation of Robert Tjian, Ph.D. from its Board of Directors, effective November 1, 2020. Dr. Tjian, who has been on the board since November 2016, will continue to support Nurix as the Chairman of its Scientific Advisory Board. His leadership is expected to guide Nurix's research on E3 ligases, a target class critical for developing therapies for cancer. The company aims to advance multiple drug candidates into clinical trials, enhancing its potential in cancer treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.11%
Tags
management
Rhea-AI Summary

Nurix Therapeutics Inc. (NRIX) reported its third-quarter financial results for 2020, highlighting a significant IPO that raised approximately $238.5 million in gross proceeds. Despite challenges from the COVID-19 pandemic, the company is on track for multiple IND filings, including upcoming submissions for its lead drug candidates NX-2127 and NX-1607. The net loss attributed to common stockholders was $18.5 million or ($0.59) per share, with total cash holdings reaching $395.1 million as of August 31, 2020, indicating a strong financial position to support ongoing clinical development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.18%
Tags

FAQ

What is the current stock price of Nurix Therapeutics (NRIX)?

The current stock price of Nurix Therapeutics (NRIX) is $19.83 as of December 20, 2024.

What is the market cap of Nurix Therapeutics (NRIX)?

The market cap of Nurix Therapeutics (NRIX) is approximately 1.4B.

What does Nurix Therapeutics, Inc. specialize in?

Nurix Therapeutics specializes in discovering, developing, and commercializing therapies that modulate cellular protein levels to treat cancer, inflammatory conditions, and other diseases.

What is the significance of Nurix's DELigase platform?

DELigase is Nurix's proprietary drug discovery platform that identifies and advances novel drug candidates targeting E3 ligases, crucial enzymes in protein regulation.

Who are Nurix's major partners?

Nurix has strategic collaborations with industry leaders like Celgene, Sanofi, Gilead, and Pfizer to develop next-generation therapies.

What are some of Nurix's key drug candidates?

Key drug candidates include NX-2127, an orally available BTK degrader for B-cell malignancies, and NX-1607, a CBL-B inhibitor for immuno-oncology.

How has Nurix performed financially in recent quarters?

Nurix reported increased revenue in the first quarter of 2024 due to collaborations and achieved research milestones, with substantial cash reserves supporting ongoing projects.

Where is Nurix Therapeutics headquartered?

Nurix Therapeutics is headquartered in San Francisco, California.

What recent leadership changes have occurred at Nurix?

Julia P. Gregory has been elected as the new board chair, succeeding Dr. David L. Lacey, who will continue to serve on the board and its committees.

What is the focus of Nurix's collaboration with Sanofi?

The collaboration with Sanofi focuses on developing targeted protein degraders for inflammatory conditions, including the STAT6 pathway.

What are Nurix's plans for NX-5948?

Nurix plans to continue clinical trials for NX-5948, a BTK degrader, and explore its use in treating B-cell malignancies with CNS involvement.

How can I learn more about Nurix Therapeutics?

For more information, visit Nurix's official website at http://www.nurixtx.com.

Nurix Therapeutics, Inc.

Nasdaq:NRIX

NRIX Rankings

NRIX Stock Data

1.41B
69.46M
1.45%
98.43%
13.56%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SAN FRANCISCO